Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
II-KEY-SARS-CoV-2 peptide vaccine
- Development stage
- Unknown
- Lead developer
- Generex Biotechnology
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The II-KEY-SARS-CoV-2 peptide vaccine is a synthetic multi-peptide COVID-19 vaccine candidate developed using the patented Ii-Key technology. This approach links immunogenic SARS-CoV-2 viral epitopes (peptides) to the Ii-Key moiety, which enhances antigen presentation and immune activation. The design aims to stimulate both cellular (T cell) and humoral (antibody) immune responses by presenting multiple HLA class II-restricted peptides from different SARS-CoV-2 proteins. The goal is to induce broad-spectrum protective immunity with long-lasting immunologic memory while minimizing off-target immune responses such as cytokine storm. The development strategy includes ex-vivo screening of candidate peptides for optimal T-cell and B-cell activation before clinical use[1][2][3].
- Brand names
- Ii-Key-SARS-CoV-2 coronavirus vaccineIi-Key-SARS-CoV2 coronavirus vaccineIi-Key-SARS-CoV 2 coronavirus vaccine
- Other names
- Ii-Key multivalent peptide vaccineIi-Key SARS-CoV-2 vaccine
02
Targets
MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on II-KEY-SARS-CoV-2 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on II-KEY-SARS-CoV-2 peptide vaccine.